BY Richard Summerfield
Drug manufacturer GSK has agreed to acquire US biopharmaceutical firm IDRx, which is developing a therapy for the treatment of gastrointestinal stromal tumours (GIST).
Under the terms of the deal, GSK, Britain’s second-biggest drugmaker behind AstraZeneca, will pay $1bn upfront, with potential for an additional $150m success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. GIST are the most common subtype of soft tissue sarcoma, with up to 120,000 patients diagnosed globally every year.
GSK will also be responsible for success-based milestone payments as well as tiered royalties for IDRX-42 owed to Germany’s Merck KGaA.
The deal will add to GSK’s growing portfolio in gastrointestinal cancers and is a continuation of its M&A strategy: acquiring assets designed to treat validated targets with unmet need. The company agreed a $2bn acquisition of Bellus Health and a $1.9bn takeover of Sierra Oncology in 2023 and 2022 respectively.
Since she became GSK’s chief executive in 2017, Emma Walmsley has been making acquisitions to boost key areas, after slimming down the overall drugs portfolio. Sales of vaccines, one of GSK’s strengths, have been falling.
The deal comes just one month after GSK gained an exclusive option to obtain a licence to develop and commercialise Duality Biologics preclinical antibody-drug conjugate, DB-1324, which leverages DualityBio’s duality immune toxin antibody conjugate platform against a gastrointestinal cancer target.
IDRX-42 is currently being evaluated in a phase 1/1b trial among GIST patients who have received second-line or more treatment. Data from the study, dubbed StrateGIST 1, demonstrate a manageable safety profile and favourable durability, according to GSK. IDRX-42 has gained FDA fast-track designation for treating patients with GIST after disease progression on or intolerance to imatinib, plus an orphan drug tag for GIST.
“IDRX-42 complements our growing portfolio in gastrointestinal cancers,” said Luke Miels, chief commercial officer of GSK. “This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical need, despite existing approved products.”
“We are excited by the early data from IDRX-42 and its unique ability to target all clinically relevant KIT mutations present in GIST, a major gap in the current standard of care,” said Tony Wood, chief scientific officer of GSK. “We look forward to accelerating its development in 2025 to redefine treatment.”
“We are looking forward to working with GSK to advance IDRX-42 for patients with GIST given there have been no major advances to the standard of care for almost 20 years,” said Tim Clackson, chief executive of IDRx. “Combining our experience to date with GSK’s expertise in GI cancers, global clinical development capability, and strong commercial presence in oncology will help to accelerate the development of this novel medicine for patients.”
News: GSK to buy US biotech firm IDRx for up to $1.15 billion